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In April 2017, following the results of the RATIFY trial (1), midostaurin, a multikinase FLT3
inhibitor, became the ﬁrst FDA approved targeted agent for the treatment of acute myeloid
leukemia (AML) (2). The addition of midostaurin to standard induction therapy with anthracycline
and cytarabine (7 + 3) rapidly became the new standard of care for treatment-naïve, ﬁt patients with
FLT3-mutated (FLTmut+) AML (3). More recently, gilteritinib, a selective FLT3 inhibitor, showed
superiority to chemotherapy in the treatment of relapsed or refractory FLTmut+ AML (4).
With two FLT3 inhibitors now approved by the FDA—that is, the more selective gilteritinib and
the less selective midostaurin—the question of which FLT3 inhibitor to use in combination with
chemotherapy in the upfront setting has become the subject of much debate (5–7). Leukemia
physicians are faced with the choice of using a more selective agent in the front line vs. reserving that
agent for the time of relapse. Here, we evaluate the rationale for both approaches.
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What Is FLT3?
Fms-like Tyrosine Kinase 3 (FLT3) is a type III receptor tyrosine kinase (RTK) expressed on
hematopoietic stem cells that is well known to play a key role in hematopoietic expansion. Wild type
FLT3 exists in the inactive monomeric conformation, which is maintained by the auto-inhibitory
interaction of the juxtamembrane and internal kinase domains and inhibits ATP-binding. When
FLT3 ligand binds the external domain, the receptor dimerizes, releasing of the inhibitory
interaction and activating the kinase domain to undergo autophosphorolyation and, via signaling
of the PI3K/AKT, MAPK and JAK/STAT pathways, promote cell survival and proliferation (8).
FLT3 is mutated in approximately 25–35% of patients with AML (9). Mutations occur either as
internal tandem duplications (ITD), which occur in approximately 25% of AML, or as tyrosine
kinase domain (TKD) mutations, which occur in approximately 7% of AML. ITD mutations are inframe insertions which occur primarily in the juxtamembrane domain, disrupting the autoinhibitory function of this domain and yielding constitutive FLT3 activation (8). It has long been
understood that patients with FLT3-ITD mutation have signiﬁcantly poorer survival than their
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FLT3-wild type counterparts (9–11) regardless of co-occurring
mutations and other cytogenetic abnormalities (12). The
pathologic signiﬁcance of TKD mutations, which and are
primarily point mutations, is less well understood with the
exception of D835 mutations, an activating mutation which is
also known to confer resistance to some FLT3 inhibitors.
The European Leukemia Net (ELN) classiﬁes the prognostic
import of FLT3-ITD mutation status based on the presence of
co-occurring mutation in nucleophosmin 1 (NPM1) and the
FLT3-ITD allelic ratio (AR). The FLT3-ITD AR is determined
using DNA fragment analysis as the ratio of the area under the
curve “FLT3-ITD” divided by the area under the curve “FLT3wild type”. A low AR (FLT3-ITDlow) is deﬁned as <0.5 and a high
AR (FLT3-ITDhigh) is deﬁned as ≥0.5. Patients with FLT3-ITD
mutation are characterized as favorable risk if they are FLT3ITDlow and have a co-occurring NPM1 mutation. Patients with
FLT3-ITD mutation are characterized as intermediate risk if they
are FLT3-ITDlow and are NPM1 wild type (without other highrisk genetic lesions) or if they are FLT3-ITDhigh and have a cooccurring NPM1 mutation. Patients with FLT3-ITD mutation
are characterized as adverse risk if they are FLT3-ITDhigh and are
NPM1 wild type (13).

DISCUSSION: WHICH FLT3 INHIBITOR
SHOULD BE USED FOR UPFRONT
COMBINATION THERAPY IN FLT3MUTATED AML
Two FLT3 inhibitors have been approved for the treatment of
FLT3-mutated AML: midostaurin and gilteritinib. Based on the
results of the RATIFY trial, midostaurin was approved in
combination with cytotoxic chemotherapy for the upfront
treatment of FLTmut+ AML (2). In May, 2019, following early
results of the ADMIRAL trial (4), the FDA approved gilteritinib
for the treatment of relapsed or refractory FLTmut+ AML with a
detectable FLT3 mutation (15). Since that time, promising early
data has emerged regarding the use of gilteritinib in combination
with 7 + 3 in the upfront setting (16).
The promising nature of these results prompted us to raise the
question of whether upfront combination treatment with a
multikinase inhibitor, such as midostaurin, or a selective FLT3
inhibitor, such as gilteritinib, is a more logical approach. While it
may be argued that this debate is premature, particularly since a
clinical trial is currently ongoing to address this exact question
(NCT03836209) (17), we argue that it will not be long until the
ﬁnal results of gilteritinib combined with chemotherapy in
treatment-naïve patients will be available; and we will then,
without a randomized comparison, be forced to choose
between these two approaches. Further, if these results remain
positive, it may be hard to recruit to a trial randomizing these
two agents due to lack of equipoise.

What Are the Characteristics
of FLT3 Inhibitors?
FLT3 inhibitors are classiﬁed both by selectivity of RTK binding
(multikinase inhibitors vs. selective FLT3 inhibitors) and by site
of binding FLT3 (type I vs. type II inhibitors). First generation
FLT3 inhibitors, such as sorafenib, sunitinib and midostaurin,
are unselective and bind multiple type III RTKs [e.g., platelet
derived growth factors alpha and beta, stem cell factor receptor
(KIT) and colony stimulating factor 1 receptor] and are therefore
referred to as multikinase inhibitors. Second generation
inhibitors, such as quizartinib, crenolanib and gilteritinib, are
more selective and bind FLT3 only or a small number of
additional RTKs (14).
Type I inhibitors bind FLT3 at the ATP-binding site in either
the active or inactive conformation and therefore have activity in
both ITD- and TKD-mutated patients. Type II inhibitors,
conversely, bind the hydrophobic region adjacent to the ATPbinding site which is only accessible in the inactive
conformation, thereby preventing FLT3 activation. TKD
mutations, most notably D835 mutations, cause the FLT3
receptor to favor the active conformation thereby precluding
binding of type II inhibitors (14). Table 1 summarizes the
classiﬁcation of various FLT3 inhibitors.

The Case for Use of Midostaurin in Initial
Induction Therapy in FLT3-Mutated AML
Data for Upfront Midostaurin: The RATIFY Trial
The RATIFY trial (1) was a multinational, double-blinded, placebocontrolled randomized trial evaluating the addition of midostaurin
on days 8–21 to conventional chemotherapy (7 + 3) in treatmentnaive FLTmut+ AML patients age 18–59 years old. Patients with both
FLT3-ITD and FLT3-TKD mutations were included so long as
mutant to wild type allelic ratio (the proportion of cells with mutant
FLT3 to wild type FLT3) was ≥0.05. Patients were stratiﬁed by type
of FLT3 mutation (TKD, ITDhigh (AR >0.7) and ITDlow (AR 0.05–
0.7). Note that the deﬁnition FLT3-ITDlow vs FLT3-ITDhigh here
differs from that used in the ELN risk stratiﬁcation classiﬁcation. If
patients remained in remission following consolidation therapy,
they could go on to receive midostaurin maintenance for up to 1
year or until allogeneic stem cell transplant (allo-SCT). The primary
endpoint was overall survival (OS).

TABLE 1 | Summary of classiﬁcation of FLT3 Inhibitors.

Type I Inhibitors
Activity in both ITD- and TKD-mutations
Type II Inhibitors
Activity in ITD-mutations only

Multikinase Inhibitors

Selective FLT3 Inhibitors

Midostaurin
Lestauritinib**
Sunitinib**
Sorafenib
Ponatinib

Crenolanib
Gilteritinib
Quizartinib

**No longer under clinical investigation for treatment of FLTmut+ AML.
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Seven hundred and seventeen patients with a median age of
47.9 years were randomized to midostaurin + chemotherapy
(n=360) vs. placebo + chemotherapy (n=357). The types of FLT3
mutations were equally distributed between the placebo and
midostaurin groups (overall, 47.6% ITDlow, 29.8% ITDhigh,
22.6% TKD). Despite very similar complete response (CR)
rates between the midostaurin (58.9%) and placebo (53.5%)
groups, the median OS in the midostaurin group was 74.7
months vs. 25.6 months with placebo, and 4-year OS was 51.4
vs. 44.2%, respectively. The authors noted that the large
difference in median OS was likely due to the tail of the
survival curves for midostaurin + chemotherapy vs. placebo +
chemotherapy falling just above and just below the 50% mark,
respectively, and that a hazard ratio (HR) of 0.78 (95% CI 0.66–
0.93) was more reﬂective of the clinical beneﬁt of the addition of
midostaurin to standard combination chemotherapy. Secondary
endpoints of event free survival (EFS) and disease free survival
(DFS) also favored the midostaurin group (8.2 months vs. 3.0
months and 26.7 months vs. 15.5 months, respectively).
The type of FLT3 mutation did not clearly impact overall
survival [HR 0.65 FLT3-TKD (CI 0.39 – 1.08) vs. 0.81 FLT3ITDlow (CI 0.6–1.11) vs. 0.80 FLT3-ITDhigh (CI 0.57–1.12)] but
when analyzed for EFS, the beneﬁt of midostaurin was primarily
seen in the TKD group.
Adverse effects were as expected for patients receiving
induction and consolidation chemotherapy. Rates of anemia
and rash were higher in the midostaurin group. More patients
in the placebo group experienced nausea.
These data clearly support the addition of midostaurin to
standard induction and consolidation therapy in FLTmut+ AML.
No other FLT3 inhibitor has shown this degree of beneﬁt in a
phase III randomized clinical trial. The beneﬁt of midostaurin on
overall survival was seen across mutation type. Thus, the answer
of which FLT3 inhibitor to use in the upfront setting is
simple: midostaurin.

wild type AML (20). Conversely, samples from patients with
relapsed AML with high FLT3mut+ allelic burden were more
sensitive to FLT3 inhibition compared to samples obtained at
diagnosis with lower FLT3mut+ AR (21). Thus, a strategy which
uses a multikinase inhibitor upfront, while delaying the use of the
more potent, selective inhibitor until relapse, may theoretically
be beneﬁcial for disease control, but this remains to be proven.

The Case for Use of Gilteritinib Combined
With Chemotherapy as Initial Induction
Therapy for FLT3-Mutated AML
Problems With RATIFY
The rates of CR in the midostaurin and placebo groups were
equivalent. Despite this, patients who received midostaurin
experienced improved EFS, DFS and OS. Although, the
survival curves overlap completely until approximately 9
months. This suggests that the beneﬁt of midostuarin is not
that it caused more remissions than placebo, but it caused deeper
remissions. Furthermore, while FLT3 mutation type did not
seem to impact response to midostaurin in terms of OS, the
EFS beneﬁt was primarily seen in the FLT3-TKD patients,
indicating that the beneﬁt in FLT3-TKD may overestimate the
beneﬁt in FLT3-ITD patients. Whether FLT3-ITD patients also
beneﬁt from midostuarin is not clearly demonstrated in RATIFY.
Additionally, the authors of RATIFY argue that the beneﬁt of
midostaurin persisted when accounting for patients undergoing
allo-SCT. While there was a trend toward increased 4-year
overall survival in patients who received midostaurin and
underwent transplant in 1st CR (CR1) vs. those who received
placebo and underwent transplant in CR1, this was not a
statistically signiﬁcant (63.7 vs. 55.7%, p=0.08). In fact, the
beneﬁt of midostaurin in transplanted patients was more
inﬂuenced by timing of transplant. Those patients who
received midostaurin and underwent transplant outside of CR1
had a median OS equal to those who received placebo and
underwent transplant outside of CR1 (14.8 months vs. 14.4
months). More patients in the midostaurin group underwent
transplant in CR1 (28%) than in the placebo group (23%). Thus,
the observed beneﬁt of midostaurin may be explained by the fact
patients in the midostaurin group underwent transplant earlier.

Upfront Multikinase Inhibitors May Inhibit Multiple
Pathways in a Polyclonal Disease
Beyond the support for upfront use of midostaurin observed in the
RATIFY trial, it has been suggested (6, 18) that the optimal
sequencing of FLT3-inhibition may be to utilize multikinase
inhibitor in the upfront setting when the disease is known to be
polyclonal (19) and to save a more targeted FLT3 inhibitor for the
time of relapse when the disease may have fewer clones and may be
more dependent on FLT3 signaling. It is important to note that this
suggestion is merely theoretical. At present, there are no available
diagnostics to determine the number or relative impact of various
malignant clones either at diagnosis or at relapse in AML. This
theory is, however, does have some support.
As the authors of RATIFY note, the observed beneﬁt of
midostaurin in FLT3-ITDlow patients, where mutations other
than FLT3 may function as drivers, may be due to the multitarget
effects of midostaurin via inhibition of alternate or additional
pathways, such as KIT. Additionally, it has been observed that
midostaurin, although not effective as a single agent, does cause
reduction of bone marrow blasts in both FLT3mut+ and FLT3
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Emerging Clinical Data for the Use of Speciﬁc FLT3
Inhibitors in the Upfront Setting
Trials evaluating selective FLT3 inhibitors crenolanib, quizartinib,
and gilteritinib in combination with traditional cytotoxic
chemotherapy in the upfront setting have shown promising
results. In June, 2019, updated results from a phase I/II study
evaluating gilteritinib combined with 7 + 3 and consolidation
treatment were presented at the annual meeting of the European
Hematology Association (EHA) (16). In this study, successive
cohorts of patients unselected for FLT3 mutation status received
dose-escalating gilteritinib (40, 80, 120, or 200 mg/day) in one of
two schedules, in combination with 7 + 3 (Schedule 1: Days 4–17,
Schedule 2: Days 8–21). The maximum tolerated dose (MTD) of
gilteritinib was determined to be 120 mg which was evaluated in a
dose expansion cohort. As of October 2018, 68 patients had enrolled
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quizartinib, retained sensitivity to multikinase inhibitors
midostaurin, sunitinib and sorafenib (25). Additionally,
Williams, et al. have shown that samples from patients with
FLT F691L mutation retain sensitivity to multikinase inhibitors,
speciﬁcally lestaurtinib and midostaurin (26). These data suggest
that, potentially, FLT3 F691L-mutated disease could be
successfully treated with midostaurin in the relapse setting.

[median age, 59.5 years (range, 23–77)]. Thirty-six patients (54.5%)
were FLT3mut+ (FLT3-ITD, n=25; FLT3-TKD D835, n=7; FLT3ITD and -TKD D835, n=1; other FLT3 mutation, n=3). Toxicity
was as expected for patients receiving induction therapy.
Remarkably, the composite CR rate of FLT3mut+ patients
receiving gilteritinib on Schedule 1 (n=22) was 100% and on
Schedule 2 (n=11) was 81.8% with a median DFS of 297 days.
High CR rates have also been observed with 7 + 3 combined with
crenolanib (72%) (22) and quizartinib (84%) (23). While these
results are early and numbers are small, the high CR rates achieved
across the board with selective FLT3 inhibitors certainly surpass the
59% CR rate observed in RATIFY, suggesting that the beneﬁt of
selective FLT3 inhibitors is not just in depth of response, as with
midostaurin, but that more patients may respond overall.

CONCLUSION
Midostaurin remains the only FLT3 inhibitor FDA approved for
the upfront treatment of FLT3 mutated AML. The data for use of
newer, more selective inhibitors in treatment-naïve patients is
rapidly evolving, and soon we may be forced to choose between
several FLT3 inhibitors without randomized data directly
comparing their clinical efﬁcacy. Here, we have discussed the
merits of these two approaches and the data to support them. At
our institution, we are currently using midostaurin in addition to
7 + 3 for upfront management of FLT3-ITD AML. We look
forward to the release of the ﬁnal phase II date with gilteritinib in
this setting. Further investigation is needed to determine the
optimal sequencing of therapies for these complex patients.

The Argument Against Using a More Speciﬁc FLT3
Inhibitor at Relapse for Oligoclonal Disease
During analysis of the ADMIRAL trial, samples from patients
who relapsed on gilteritinib were evaluated with next generation
sequencing (NGS) for new mutations acquired at relapse (24). Of
the 40 patients analyzed, mutations downstream of FLT3 in the
Ras/MAPK pathway were the most commonly acquired
mutations in 18 (45%) patients. This argues against the
theoretical case for “saving” selective FLT3 inhibitors for the
time of relapse, as mutations downstream of FLT3 may confer
resistance to any FLT3 inhibitors.
The next most common mutations occurring in 6 patients
(15%) were mutations in FLT3 itself with the majority (5/6)
being FLT3 F691L, or the so called “gatekeeper mutations.” In an
in vitro analysis by Albers, et al., a patient harboring the FLT3
F691L mutation, while resistant to the selective FLT3 inhibitor
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